170,208 research outputs found
La vecchiaia di Foppa
No full textIl testo ripercorre l'attività di Vicenzo Foppa (Brescia 1430 c. - 1515 c.) nel corso dell'ultimo decennio del Quattrocento e dei primi anni del nuovo secolo. Particolare attenzione è dedicata al dialogo intrapreso del pittore con le novità che scuotevano in quella stagione la pittura milanese, dalle esperienze prospettiche di Bramantino alla diffusione del linguaggio leonardesco
Un progetto, uno spazio, una prospettiva. Indagine riflettografica della Pala Bottigella di Vincenzo Foppa
No full textL'indagine riflettografica della Pala Bottigella, unitamente a quella radiografica, permette di chiarire alcuni aspetti particolarmente importanti delle modalità esecutive adottate da Foppa durante l'esecuzione della Pala Bottigella. Si ha conferma, tra l'altro, della presenza del Beato Domenico e della Beata Sibilla Biscossi fin dal primo momento della progettazione dell'opera
Medicina interna sistematica. Con CD-ROM Castagna, A: Novati, R; Tambussi, G; Uberti Foppa C Capitolo 97 - Infezioni in situazioni particolari
No full text
Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use
No full textMultiple direct-acting antiviral (DAA)-based regimens are currently approved that provide one or more interferon-free treatment options for hepatitis C virus (HCV) genotypes (G) 1â6. The choice of a DAA regimen, duration of therapy, and use of ribavirin depends on multiple viral and host factors, including HCV genotype, the detection of resistance-associated amino acid (aa) substitutions (RASs), prior treatment experience, and presence of cirrhosis. In regard to viral factors that may guide the treatment choice, the most important is the infecting genotype because a number of DAAs are genotype-designed. The potency and the genetic barrier may also impact the choice of treatment. One important and debated possible virologic factor that may negatively influence the response to DAAs is the presence of baseline RASs. Baseline resistance testing is currently not routinely considered or recommended for initiating HCV treatment, due to the overall high response rates (sustained virological response >90%) obtained. Exceptions are patients infected by HCV G1a when initiating treatment with simeprevir and elbasvir/grazoprevir or in those with cirrhosis prior to daclatasvir/sofosbuvir treatment because of natural polymorphisms demonstrated in sites of resistance. On the basis of these observations, first-line strategies should be optimized to overcome treatment failure due to HCV resistance
Critically appraised topic for the most effective and safe treatment for canine generalised demodicosis
No full textBackground
Canine generalised demodicosis is an inflammatory parasitic skin disease caused by an excessive proliferation of Demodex spp. Generalized demodicosis is a severe skin disease, that can be life threatening if not treated properly. Many of the current treatment options are not licensed for the treatment of generalised demodicosis, it have a low safety margin and may be poorly efficacious and time-consuming for the owner; there is a need for a safe, efficacious treatment for canine demodicosis. Our objective was to systematically review the literature to determine the most effective and safe topical or systemic therapy for canine generalised demodicosis. Single case reports and case series with fewer than five patients were not reviewed as they were considered to be poor quality evidence. A detailed literature search identified 21 relevant clinical trials and these were critically assessed.
Results
The analysis of the best available evidence on March 5, 2018, suggests that six are the most effective and safe treatments for generalised canine demodicosis including (in alphabetical order): doramectin (oral or parenteral); fluralaner (oral); imidacloprid/moxidectin (topical); ivermectin (oral, not as first choice treatment); milbemycin oxime (oral); and sarolaner (oral). There was insufficient evidence to allow comment on the appropriateness of other treatment protocols for canine generalised demodicosis in this CAT.
Conclusions
In our critical appraisal of the best scientific literature, there is evidence for recommending the use of 6 therapeutic options against demodectic mange. Further, in vivo, controlled, randomized and blinded clinical trials are required, to evaluate new therapies
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts
No full textThirty-one AIDS patients were typed for HLA A, B, C, and DR antigens. We confirmed that frequency of B35 is significantly higher in patients than in controls. No significant frequency differences in other HLA antigens were found. The analysis of HLA distribution in AIDS patients by risk categories suggests that B35 is a major risk factor, primarily mainly for patients belonging to the category of intravenous (IV) drug addicts
Utilisation of a Heat Pump in Pig Breeding for Energy Saving and Climate and Ammonia Control
No full text- …
